Humacyte, Inc. (NASDAQ:HUMA) Director Purchases $20,194.00 in Stock

Humacyte, Inc. (NASDAQ:HUMA) Director Michael T. Constantino acquired 4,600 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were bought at an average cost of $4.39 per share, for a total transaction of $20,194.00. Following the completion of the acquisition, the director now directly owns 16,950 shares of the company’s stock, valued at approximately $74,410.50. The trade was a 37.25 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Humacyte Price Performance

Shares of HUMA stock traded up $0.18 during mid-day trading on Wednesday, hitting $4.43. 2,024,921 shares of the stock were exchanged, compared to its average volume of 2,417,861. The firm has a fifty day moving average of $5.17 and a 200 day moving average of $6.13. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61. Humacyte, Inc. has a 52-week low of $2.45 and a 52-week high of $9.97. The company has a market cap of $557.56 million, a PE ratio of -3.17 and a beta of 1.38.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on HUMA. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Humacyte in a report on Wednesday, November 13th. Benchmark reissued a “buy” rating and set a $15.00 price objective on shares of Humacyte in a report on Thursday, October 10th. TD Cowen reaffirmed a “buy” rating and issued a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a report on Monday, September 9th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of Humacyte in a report on Thursday, November 21st. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Humacyte presently has an average rating of “Buy” and a consensus target price of $13.00.

Institutional Investors Weigh In On Humacyte

Several hedge funds have recently modified their holdings of the company. nVerses Capital LLC acquired a new position in shares of Humacyte during the 2nd quarter worth about $28,000. Concurrent Investment Advisors LLC acquired a new position in shares of Humacyte during the 3rd quarter worth about $75,000. Principal Financial Group Inc. acquired a new position in shares of Humacyte during the 2nd quarter worth about $83,000. FORA Capital LLC acquired a new position in shares of Humacyte during the 3rd quarter worth about $96,000. Finally, Profund Advisors LLC acquired a new position in shares of Humacyte during the 2nd quarter worth about $97,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.